SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is based in Rolle, Switzerland.
Data-Driven Growth | SOPHiA GENETICS expands its customer base, adding 20 new clients and achieving 17% year-over-year volume growth, showcasing resilience in a challenging market |
Market Headwinds | Explore the impact of conservative biopharma spending and regional softness on SOPHiA's revenue projections, and the company's strategic response |
Future Prospects | Delve into SOPHiA's upcoming MSK liquid biopsy offerings and their potential to drive significant revenue growth in fiscal year 2025 |
Financial Outlook | Analyst price targets range from $5 to $7, with management confident in achieving operating profitability within two years despite current market challenges |
Metrics to compare | SOPH | Sector Sector - Average of metrics from a broad group of related Technology sector companies | Relationship RelationshipSOPHPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.9x | −1.7x | −0.5x | |
PEG Ratio | 0.38 | −0.01 | 0.00 | |
Price/Book | 2.8x | 1.4x | 2.6x | |
Price / LTM Sales | 3.1x | 1.7x | 3.3x | |
Upside (Analyst Target) | 106.5% | 20.9% | 43.5% | |
Fair Value Upside | Unlock | 7.3% | 6.9% | Unlock |